Lumos Diagnostics (ASX:LDX) received the largest single purchase order for the company's point-of-care respiratory test, FebriDx, worth $126,000 from iMedical, according to a Wednesday filing with the Australian bourse.
The US Food and Drug Administration cleared FebriDx to be marketed in the US in July 2023 as an aid in diagnosing bacterial acute respiratory infection and distinguishing them from non-bacterial causes, the filing said.
Shares rose nearly 4% in afternoon trade Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.